In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) closed the day trading at $3.82 down -5.68% from the previous closing price of $4.05. In other words, the price has decreased by -$5.68 from its previous closing price. On the day, 1.45 million shares were traded. MREO stock price reached its highest trading level at $4.14 during the session, while it also had its lowest trading level at $3.78.
Ratios:
For a better understanding of MREO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on June 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.
On August 12, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $4.Cantor Fitzgerald initiated its Overweight rating on August 12, 2022, with a $4 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 592657728 and an Enterprise Value of 2889440000. Its current Enterprise Value per Revenue stands at 2889.44 whereas that against EBITDA is -77.101.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $1.86. The 50-Day Moving Average of the stock is -10.42%, while the 200-Day Moving Average is calculated to be 1.64%.
Shares Statistics:
Over the past 3-months, MREO traded about 753.51K shares per day on average, while over the past 10 days, MREO traded about 588480 shares per day. A total of 153.76M shares are outstanding, with a floating share count of 141.76M. Insiders hold about 7.81% of the company’s shares, while institutions hold 57.82% stake in the company. Shares short for MREO as of 1730332800 were 4565429 with a Short Ratio of 6.06, compared to 1727654400 on 4881549. Therefore, it implies a Short% of Shares Outstanding of 4565429 and a Short% of Float of 3.52.
Earnings Estimates
The current assessment of Mereo Biopharma Group Plc ADR (MREO) involves the perspectives of 2 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.01, with high estimates of $0 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.05 and -$0.05 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.03, with 4.0 analysts recommending between $0.01 and -$0.05.
